Bullish Moving Averages
9
Bearish Moving Averages
2
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Open Price
1531.00Prev. Close
1394.3000Volume
238923.00Value
349197910.65Fundamentals
Market Cap
27637.70
Price to Earnings
0.00
Price to Book Value
8.90
Dividend Yield
0.00
PE to Growth
0.00
Op Revenue TTM
0.00
Net Profit TTM
0.00
Cash From Operating Activity
1097.24
Return on Equity %
16.87
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
19 Sep, 2024
44.3
Week
46.3
Month
51.8
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
1480.85
PIVOT
First Resistance
1520.65
Second Resistance
1579.75
Third Resistance
1619.55
First Support
1421.75
Second Support
1381.95
Third Support
1322.85
Relative Strength Index
59.11
Money Flow Index
77.67
MACD
34.85
MACD Signal
26.94
Average True Range
53.61
Average Directional Index
36.29
Rate of Change (21)
7.19
Rate of Change (125)
Day Commodity Channel Index
136.2
Day Williams %R
-58.5
BETA
1 Month
0.36
3 Month
1 Year
3 Year
PRICE CHANGE ANALYSIS
↑ 2.33%
1 Week
Low
High
1410
1580
↑ 16.12%
1 Month
Low
High
1259.65
1580
↑ 45%
3 Months
Low
High
1225
1580
↑ 45%
6 Months
Low
High
1225
1580
↑ 45%
1 Year
Low
High
1225
1580
13 Sep 2024
Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Acquisition
Pursuant to Regulation 30 of the SEBI ( Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we would like to inform that a Committee of the Board of Directors of the Company in their meeting held today i.e. September 13, 2024, has inter-alia approved the incorporation of a wholly-owned subsidiary in Pune, Maharashtra, India.
19 Aug 2024
Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated August 8, 2024, please find enclosed the transcript of the Earnings Call for the Q1 FY25, held on Wednesday, August 14, 2024 at 8.30 a.m. (IST).
15 Aug 2024
Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith extracts of the Unaudited Financial Results of the Company for the quarter ended June 30, 2024, as published in the newspapers viz. "Financial Express" and "Loksatta" on August 15, 2024.
14 Aug 2024
Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our intimation dated August 8, 2024, regarding earnings call, the audio recording of the call held today is available on our website.
13 Aug 2024
Emcure Pharmaceuticals Ltd - 544210 - Outcome Of Board Meeting Held On August 13, 2024
Outcome of Board Meeting held on August 13, 2024
13 Aug 2024
Emcure Pharmaceuticals Ltd - 544210 - Outcome Of Board Meeting Held On August 13, 2024
Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Unaudited Financial Results for the quarter ended June 30, 2024, along with the Limited Review Reports on the aforesaid results as issued by the B S R & Co. LLP, Chartered Accountants, Auditors of the Company, enclosed as Annexure A. Press Release outlining key updates on the aforesaid results are enclosed as Annexure B.
13 Aug 2024
Emcure Pharmaceuticals Ltd - 544210 - Board Meeting Outcome for Outcome Of Board Meeting Held On August 13, 2024
The Board of Directors of the Company at its meeting held today i.e. Tuesday, August 13, 2024 has inter-alia approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2024, as reviewed and recommended by the Audit Committee. Pursuant to Regulation 33 of the Listing Regulations, we are enclosing herewith the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2024, along with the Limited Review Reports on the aforesaid Results as issued by B S R & Co. LLP, Chartered Accountants, Auditors of the Company, enclosed as Annexure A. Press Release outlining key updates on the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2024, is also enclosed herewith as Annexure B.
13 Aug 2024
Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 read with Para A of Part of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform that CARE Ratings Limited ("CARE"), has upgraded its ratings on the Bank Facilities of Emcure Pharmaceuticals Limited ("the Company"), vide its press release as received by the Company on August 13, 2024.
13 Aug 2024
Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2025, as amended, we wish to inform that CRISIL Ratings Limited ("CRISIL") has upgraded its ratings on the Bank Loan Facilities of Emcure Pharmaceuticals Limited.
08 Aug 2024
Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation for Earnings Call for Investors/ Analysts to be held on Wednesday, August 14, 2024 at 8.30 a.m. (IST) to discuss the Company''s unaudited financial results (standalone and consolidated) and performance for the quarter ended June 30, 2024.
